Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.

摘要: Abstract Background Some evidence indicates that androgen-deprivation therapy (ADT) increases the risk of diabetes and cardiovascular disease. To date, few studies have investigated whether this also cerebrovascular events. Objective determine different types ADT increase stroke/transient ischaemic attacks (TIAs) in patients with prostate cancer. Design, setting, participants We conducted a population-based cohort study using nested case-control analysis within United Kingdom's General Practice Research Database population. The included all at least 40 yr age newly diagnosed cancer between January 1, 1988, December 31, 2008, followed until 2009. Cases consisted those who experienced first-ever stroke/TIA during follow-up. Up to 10 controls were matched each case on age, year entry, duration Measurements Adjusted rate ratios (RRs) associated use ADTs (gonadotropin-releasing hormone [GnRH] agonists, oral antiandrogens, combined androgen blockade, bilateral orchiectomy, others) estimated conditional logistic regression. Results limitations 22 310 cancer, for mean 3.9 yr, where 938 (rate: 10.7 per 1000/yr). Compared nonusers ADT, current users GnRH agonists (adjusted RR: 1.18; 95% confidence interval [CI], 1.00–1.39), antiandrogens 1.47; CI, 1.08–2.01), underwent orchiectomy 1.77; 1.25–2.39) an increased stroke/TIA. No statistically significant risks observed blockade other ADTs, but small numbers do not rule out possible association. Conclusions results large provide additional forms may